Pharmacology of nicotine: Addiction and therapeutics

Annual Review of Pharmacology and Toxicology

Volumn 36, Issue , 1996, Pages 597-613

  Benowitz, Neal L ^a,b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cardiovascular; cholinergic nervous system; metabolism; neuroendocrine; tobacco

Indexed keywords

NICOTINE; NICOTINE GUM; NICOTINIC RECEPTOR; TOBACCO SMOKE;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR SYSTEM; DRUG DEPENDENCE; DRUG METABOLISM; DRUG TOLERANCE; GILLES DE LA TOURETTE SYNDROME; HUMAN; INTRANASAL DRUG ADMINISTRATION; NEUROENDOCRINE SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SLEEP APNEA SYNDROME; SMOKING; TRANSDERMAL DRUG ADMINISTRATION; ULCERATIVE COLITIS;

EID: 0029979162     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pa.36.040196.003121     Document Type: Review

References (93)

1. Benowitz NL. 1988. Pharmacologic aspects of cigarette smoking and nicotine addiction. N. Engl. J. Med. 319:1318-30
2. Benowitz NL. 1992. Cigarette smoking and nicotine addiction. Med. Clin. N. Am. 76:415-37
3. Changeux JP, Galzi JL, Devillers-Thiery A, Betrand D. 1992. The functional architecture of the acetylcholine nicotinic receptor explored by affinity labeling and site-directed mutagenesis. Q. Rev. Biophys. 25:395-432
4. 125I]α-bungarotoxin. J. Neurosci. 5:1307-15
5. McGehee DS, Role LW. 1995. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu. Rev. Physiol. 57: 521-46
6. 7: a nicotinic cation channel highly permeable to calcium. J. Neurosci. 13:596-604
7. Lena C, Changeux J-P. 1993. Allosteric modulations of the nicotinic acetylcholine receptor. Trends Neurosci. 16: 181-86
8. Wonnacott S. 1990. The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol. Sci. 11:216-19
9. Collins AC, Luo Y, Selvaag S, Marks MJ. 1994. Sensitivity to nicotine and brain nicotinic receptors are altered by chronic nicotine and mecamylamine infusion. J. Pharmacol. Exp. Ther. 271: 125-33
10. 3H]nicotine binding sites in human brain. J. Neurochem. 50:1243-47
11. Madhok TC, Beyer HS, Sharp BM. 1994. Protein kinase A regulates nicotinic cholinergic receptors and subunit messenger ribonucleic acids in PC 12 cells. Endocrinology 134:91-96
12. Corrigall WA, Coen KM, Adamson KL. 1994. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res. 653:278-84
13. Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED. 1993. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend. 33:23-29
14. Porchet HC, Benowitz NL, Sheiner LB, Copeland JR. 1987. Apparent tolerance to the acute effect of nicotine results in part from distribution kinetics. J. Clin. Invest. 80:1466-71
15. Byrd GD, Chang K, Greene JM, deBethizy JD. 1992. Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3′-hydroxycotinine in smokers. Drug Metab. Dispos. 20:192-97
16. Benowitz NL, Jacob P III, Fong I, Gupta S. 1994. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J. Pharmacol. Exp. Ther. 268:296-303
17. Benowitz NL, Jacob P III. 1994. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin. Pharmacol. Ther. 56:483-93
18. Benowitz NL, Jacob P III, Sachs DPL. 1995. Deficient C-oxidation of nicotine. Clin. Pharmacol. Ther. 57: 590-94
19. Clarke PBS, Pert A. 1985. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res. 348:355-58
20. Corrigall WA, Coen KM, Franklin KBJ, Clarke PBS. 1992. The mesolimbic dopamine system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107:285-89
21. Corrigall WA. 1993. Nicotine addiction: considerations in the therapeutic use of nicotine. Med. Chem. Res. 2:603-11
22. Henningfield JE. 1984. Behavioral pharmacology of cigarette smoking. In Advances in Behavioral Pharmacology, ed. T Thompson, PB Dews, JE Barrett, pp. 131-210. New York: Academic
23. Hughes JR, Hatsukami D. 1986. Signs and symptoms of tobacco withdrawal. Arch. Gen. Psychiatry 43:289-94
24. LeHouezec J, Halliday R, Benowitz NL, Callaway E, Naylor H, Herzig K. 1994. A low dose of subcutaneous nicotine improves information processing in nonsmokers. Psychopharmacology 114: 628-34
25. Spilich GJ, June L, Renner J. 1992. Cigarette smoking and cognitive performance. Br. J. Addict. 87:1313-26
26. Rose JE, Behm FM, Levin ED. 1993. Role of nicotine dose and sensory cues in the regulation of smoke intake. Pharmacol. Biochem. Behav. 44:891-900
27. Pickworth WB, Herning RI, Henningfield JE. 1989. Spontaneous EEG changes during tobacco abstinence and nicotine substitution in human volunteers. J. Pharmacol. Exp. Ther. 251: 976-82
28. McNamara D, Larson DM, Rapoport SI, Soncrant TT. 1990. Preferential metabolic activation of subcortical brain areas by acute administration of nicotine to rats. J. Cereb. Blood Flow Metab. 10:48-56
29. Pickworth WB, Bunker EB, Henningfield JE. 1994. Transdermal nicotine: reduction of smoking with minimal abuse liability. Psychopharmacology 115: 9-14
30. Quillen JE, Rossen JD, Oskarsson HJ, Minor RL Jr, Lopez JAG, Winniford MD. 1993. Acute effect of cigarette smoking on the coronary circulation: constriction of epicardial and resistance vessels. J. Am. Coll. Cardiol. 22:642-47
31. Kaijser L, Berglund B. 1985. Effect of nicotine on coronary blood-flow in man. Clin. Physiol. 5:541-52
32. Winniford MD, Wheelan KR, Kremers MS, Ugolini V, Van Den Berg E Jr, et al. 1986. Smoking-induced coronary vasoconstriction in patients with atherosclerotic coronary artery disease: evidence for adrenergically mediated alterations in coronary artery tone. Circulation 73:662-67
33. Porchet HC, Benowitz NL, Sheiner LB. 1988. Pharmacodynamic model of tolerance: application to nicotine. J. Pharmacol. Exp. Ther. 244:231-36
34. Pfueller SL, Burns P, Mak K, Firkin BG. 1988. Effects of nicotine on platelet function. Haemostasis 18:163-69
35. Folts JD, Bonebrake FC. 1982. The effects of cigarette smoke and nicotine on platelet thrombus formation in stenosed dog coronary arteries: inhibition with phentolamine. Circulation 65: 465-69
36. Nowak J, Murray JJ, Oates JA, Fitzgerald GA. 1987. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 76:6-14
37. 2 and prostacyclin metabolites in young men. Circulation 83:1698-704
38. Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q. 1993. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J. Am. Coll. Cardiol. 22:1159-67
39. Mundal HH, Hjemdahl P, Gjesdal K. 1995 Acute effects of low dose nicotine gum on platelet function in nonsmoking hypertensive and normotensive men. Eur. J. Clin. Pharmacol. 47:411-16
40. Chahine R, Calderone A, Navarro-Delmasure C. 1990. The in vitro effects of nicotine and cotinine on prostacyclin and thromboxane biosynthesis. Prostaglandins Leukot Essent Fatty Acids 40:261-66
41. Williamson DF, Madans J, Anda RF, Kleinman JC, Giovino GA, Byers T. 1991. Smoking cessation and severity of weight gain in a national cohort. N. Engl. J. Med. 324:739-45
42. Perkins KA. 1992. Metabolic effects of cigarette smoking. J. Appl. Physiol. 72: 401-9
43. Arcavi L, Jacob P III, Hellerstein M, Benowitz NL. 1994. Divergent tolerance to metabolic and cardiovascular effects of nicotine in smokers with low and high levels of cigarette consumption. Clin. Pharmacol. Ther. 56: 55-64
44. Wahren J. 1990. Nicotine, cigarette smoking and energy expenditure in humans. Eur. Chem. Soc. Conf. on Nicotine, Visby, Sweden (Abstr.)
45. Hellerstein MK, Benowitz NL, Neese RA, Schwartz J, Hoh R, et al. 1994. Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers. J. Clin. Invest. 93:265-72
46. Craig WY, Palomaki GE, Haddow JE. 1989. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. Br. Med. J. 298:784-88
47. Quensel M, Agardh C-D, Nilsson-Ehle P. 1989. Nicotine does not affect plasma lipoprotein concentrations in healthy men. Scand. J. Clin. Lab. Invest. 49: 149-53
48. Baron JA, Corni RJ, Cryns V, Brinck-Johnsen T, Mercer NG. 1995. The effect of cigarette smoking on adrenal cortical hormones. J. Pharmacol. Exp. Ther. 272: 151-55
49. Seyler LE, Pomerleau OF, Fertig JB, Hunt D, Parker K. 1986. Pituitary hormone response to cigarette smoking. Pharmacol. Biochem. Behav. 24:159-62
50. Rogers DT, Iwamoto ET. 1993. Multiple spinal mediators in parenteral nicotine-induced antinociception. J. Pharmacol. Exp. Ther. 267:341-49
51. Pomerleau OF, Turk DC, Fertig JB. 1984. The effects of cigarette smoking on pain and anxiety. Addict. Behav. 9:265-71
52. Miao FJ, Dallman MF, Benowitz NL, Basbaum AI, Levine JD. 1993. Adrenal medullary modulation of the inhibition of bradykinin-induced plasma extravasation by intrathecal nicotine. J. Pharmacol. Exp. Ther. 53:6-14
53. Hopper JL, Seeman E. 1994. The bone density of female twins discordant for tobacco use. N. Engl. J. Med. 330:387-92
54. Baron JA, LeVecchia C, Levi F. 1990. The antiestrogenic effect of cigarette smoking in women. Am. J. Obstet. Gynecol. 162:502-14
55. Cassidenti DL, Pike MC, Vijod AG, Stanczyk FZ, Loso RA. 1992. A reevaluation of estrogen status in postmenopausal women who smoke. Am. J. Obstet. Gynecol. 166:1444-48
56. Kiel DP, Baron JA, Anderson JJ, Hannan MT, Felson DT. 1992. Smoking eliminates the protective effect of oral estrogens on the risk for hip fracture among women. Ann. Int. Med. 116:716-21
57. Broulik PD, Jarab J. 1993. The effect of chronic nicotine administration on bone mineral content in mice. Horm. Metab. Res. 25:219-21
58. Pauly JR, Collins AC. 1993. An autoradiographic analysis of alterations in nicotinic cholinergic receptors following 1 week of corticosterone supplementation. Neuroendocrinology 57:262-71
59. 3H]nicotine to rat brain membranes. FEBS Lett. 157:147-49
60. Fuxe K, Everitt BJ, Hokfelt T. 1979. On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons. Pharmacol. Biochem. Behav. 10: 671-77
61. Barbieri RL, York CM, Cherry ML, Ryan KJ. 1987. The effects of nicotine, cotinine and anabasine on rat adrenal 11β-hydroxylase and 21-hydroxylase. J. Steroid Biochem. 28:25-28
62. Yeh J, Barbieri RL, Friedman AJ. 1989. Nicotine and cotinine inhibit rat testis androgen biosynthesis in vitro. J. Steroid. Biochem. 33:627-30
63. Dominiak P, Fuchs G, von Toth S, Grobecker H. 1985. Effects of nicotine and its major metabolites on blood pressure in anaesthetized rats. Klin Wochenschr 63:90-92
64. Benowitz NL, Sharp DS. 1989. Inverse relation between serum cotinine concentration and blood pressure in cigarette smokers. Circulation 80:1309-12
65. Keenan RM, Hatsukami DK, Pentel PR, Thompson TN, Grillo MA. 1994. Pharmacodynamic effects of cotinine in abstinent cigarette smokers. Clin. Pharmacol Ther. 55:581-90
66. Levin ED, Westman EC, Stein RM, Carnahan E, Sanchez M, et al. 1994. Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. J Clin. Psychopharmacol. 14:41-49
67. Benowitz NL. 1995. Clinical pharmacology of transdermal nicotine. Eur J. Pharm. Biopharm. 41:168-74
68. Benowitz NL, Jacob P III, Savanapridi C. 1987. Determinants of nicotine intake while chewing nicotine polacrilex gum Clin. Pharmacol. Ther. 41:467-73
69. Johansson CJ, Olsso P, Bende M, Carlsson T, Gunnarsson PO. 1991. Absolute bioavailability of nicotine applied to different nasal regions. Eur. J. Clin. Pharmacol. 41:585-88
70. Fiore MC, Smith SS, Jorenby DE, Baker TB. 1994. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA 271:1940-47
71. Tang JL, Law M, Wald N. 1994. How effective is nicotine replacement therapy in helping people to stop smoking? Br. Med. J. 308:21-26
72. Sachs DPL, Säwe U, Leischow SJ. 1993. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch. Int. Med. 153:1881-90
73. Sutherland G, Stapleton JA, Russell MAH, Jarvis MJ, Hajek P, et al. 1992. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 340:324-29
74. Rose JE, Levin ED. 1991. Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence. Pharmacol. Biochem. Behav. 41: 219-26
75. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV. 1994 Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther. 56:86-99
76. Gourlay SG, Benowitz NL. 1995. Is clonidine an effective smoking cessation therapy? Drugs 50:197-207
77. Anda RF, Williamson DF, Escobedo LG, Mast EE, Giovino GA, Remington PL. 1990. Depression and the dynamics of smoking. JAMA 264:1541-45
78. Covey LS, Glassman AH, Stetner F. 1990. Depression and depressive symptoms in smoking cessation. Compr. Psychiatry 31:350-54
79. Calkins BM. 1989. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig. Dis. Sci. 34:1841-54
80. Pullan RD, Rhodes J, Ganesh SA. 1994. Transdermal nicotine for active ulcerative colitis. N. Engl. J. Med. 330:811-15
81. Thomas GAO, Rhodes J, Mani V, Williams GT, Newcombe RG, et al. 1995. Transdermal nicotine as maintenance therapy for ulcerative colitis. N. Engl. J. Med. 332:988-92
82. Rinne JO, Myllykyla T, Lonnberg P, Marjamaki P. 1991. A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res. 547:167-70
83. Jones GMM, Sahakian BJ, Levy R, Warburton DM, Gray JA. 1992. Effects of acute subcutaneous nicotine on attention, information processing and short- term memory in Alzheimer's disease. Psychopharmacology 108: 485-94
84. 3H]ABT-418: a novel cholinergic channel ligand. J. Pharmacol. Exp. Ther. 273:1434-41
85. Baron JA. 1986. Cigarette smoking and Parkinson's disease. Neurology 36: 1490-96
86. 3H]dopamine release from synaptosomes prepared from mouse striatum. J. Neurochem. 59:848-56
87. Fagerstrom KO, Pomerleau O, Giordani B, Stelson F. 1994. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology 116:117-19
88. Clemens P, Baron JA, Coffey D, Reeves A. 1995. The short-term effect of nicotine chewing gum in patients with Parkinson's disease. Psychopharmacology 117: 253-56
89. Fuxe K, Janson AM, Jansson A, Andersson K, Eneroth P, Agnati LF. 1990. Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after a partial di-mesencephalic hemitransection. Naunyn-Schmiedeberg's Arch. Pharmacol. 341: 171-81
90. James JR, Nordberg A. 1995. Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: emphasis on Alzheimer's disease and Parkinson's disease. Behav. Genet. 25:149-59
91. Emerich DF, Zanol MD, Norman AB, McConville BJ, Sanberg PR. 1991. Nicotine potentiates haloperidol-induced catalepsy and hypoactivity. Pharmacol. Biochem. Behav. 38:875-50
92. Silver AA, Sanberg PR. 1993. Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome [Letter]. Lancet 342:182
93. Gothe B, Strohl KP, Levin S, Cherniak NS. 1985. Nicotine: a different approach to treatment of obstructive sleep apnea. Chest 87:11-17